- Miehlke S, Hackelsberger A, Meaning A, Hatz R, Lehn N, Malfeitheiner P, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998;78:263-6.
- Meining A, Bayerdörffer E, Müller P, Miehlke S, Lehn N, Hölzel D, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch 1998;432:311-4.
- Meining A, Bayerdörffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999; 11:71720.
- Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 1997;29:671-8.
- Hansson LE, Nyren O, Hesing AW, Evans DJ, Lindgren A, Bergstöm R, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
- Stolte M, Stadelmann O, Bethke B, Burkhard G. Relationship between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995;33:89-93.
- Stolte M, Bethke B, Ruhl G, Ritter M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 1992:30:134-8.
- Stolte M, Meining A, Schmilz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:247-53.
- Meining A, Kiel G, Stolte M. Changes in Helicobacter pyloriinduced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12: 735-40.
- Meining A, Stolte M, Hatz R, Lehn N, Miehlke S, Morgner A, et al. Differing grade and distribution of gastritis in Helicobacter pylori associated diseases. Virchows Arch 1997;431:11-15.
- Lee A, Dixon MF, Danon SJ, Kuipers E, Megraud F, Larsson H, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995;7:461-5.
- El-Omar EM, Carrington M, Chow WH, McCoIl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000:404:398-402.
- Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
- Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopie resection of early gastric cancer. Cancer Epiderniol Biomarkers Prev 1997:6: 639-42.
- Bayerdörffer E, Lehn N, Hatz R, Mannes GA, Oertel H, Sauerbruch T, et al. Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology 1992; 102: 1575-82.
- Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al, and the European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002:16:167-80.
- Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, et al. Helicobacter pylori and gastric cancer: current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol 2001;7:243-7.
- Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;! 19:7-14.
- Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Nat Cancer Inst 2000:92:1881-8.
- Morgner A, Miehlke S, Stolte M, Neubauer A, Alpen B, Thiede C, et al. Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J Gastroenterol 2001:7:248-53.
Scandinavian Journal of Gastroenterology
Volume 38, 2003 - Issue 7